Functional and psychosocial impact of COVID-19 pandemic on rheumatic patients’ quality of life in Saudi Arabia

Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...     

Self-image, adolescence, and disability.

The purpose of the present study was to examine the self-image of a group of young persons with cerebral palsy. The respondents (3 girls and 4 boys, ages 12 to 17 years) were interviewed and asked to complete a personality inventory. The results from the personality inventory revealed that the respondents viewed themselves in a very positive manner and rated markedly higher than norm groups. This positive view corresponded well with the findings of the interview. The following conclusions are made: Further studies on self-image and the psychosocial development of adolescents with disabilities should (a) focus on the social interaction outside their immediate families, and (b) continue to use and develop methods where these adolescents can give voice to their own experiences and opinions.     

A randomized,double‐blind,placebo controlled,multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome

Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤45 μg/L) recruited from a cohort of 231 patients were randomly assigned in a 12‐months double‐blind, multi‐centre study of iron sucrose 1000 mg (n = 29) or saline (n = 31). The primary efficacy variable was the RLS severity scale (IRLS) score at week 11. Median IRLS score decreased from 24 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo (P = 0.123, N.S. for between treatment comparison). The corresponding scores at week 7 were 12 and 20 in the two groups (P = 0.017). Drop out rate because of lack of efficacy at 12 months was 19/31 after placebo and 5/29 patients after iron sucrose (Kaplan–Meier estimate, log rank test P = 0.0006) suggesting an iron induced superior long term RLS symptom control. Iron sucrose was well tolerated. This study showed a lack of superiority of iron sucrose at 11 weeks but found evidence that iron sucrose reduced RLS symptoms both in the acute phase (7 weeks) and during long‐term follow up in patients with variable degree of iron deficiency. Further studies on target patient groups, dosing and dosing intervals are warranted before iron sucrose could be considered for treatment of iron deficient patients with RLS. © 2009 Movement Disorder Society     

Adding Bupivacaine to High-potassium Cardioplegia Improves Function and Reduces Cellular Damage of Rat Isolated Hearts after Prolonged, Cold Storage

Background: Bupivacaine retards myocardial acidosis during ischemia. The authors measured function of rat isolated hearts after prolonged storage to determine whether bupivacaine improves cardiac protection compared with standard cardioplegia alone.

Methods: After measuring cardiac function on a Langendorff apparatus, hearts were perfused with cardioplegia alone (controls), cardioplegia containing 500 [mu]m bupivacaine, or cardioplegia containing 2 mm lidocaine; were stored at 4[degrees]C for 12 h; and were then reperfused. Heart rate and left ventricular developed pressures were measured for 60 min. Maximum positive rate of change in ventricular pressure, oxygen consumption, and lactate dehydrogenase release were also measured.

Results: All bupivacaine-treated, four of five lidocaine-treated, and no control hearts beat throughout the 60-min recovery period. Mean values of heart rate, left ventricular developed pressure, maximum positive rate of change in ventricular pressure, rate-pressure product, and efficiency in bupivacaine-treated hearts exceeded those of the control group (P < 0.001 at 60 min for all). Mean values of the lidocaine group were intermediate. Oxygen consumption of the control group exceeded the other groups early in recovery, but not at later times. Lactate dehydrogenase release from the bupivacaine group was less than that from the control group (P < 0.001) but did not differ from baseline.     

Medical removals of the Multiload IUD

In a follow-up evaluation of 3721 Multiload IUD users, the removal rate for medical reasons other than bleeding/pain was only 2.6 per 100 women at three years. Most of these removals were for reasons that appeared to be unrelated to IUD use. The removal rate for pelvic inflammatory disease was 0.3 per 100 woman years. Women were followed up for up to three years after removal of their IUDs. Among women with PID at least 70% of those who desired pregnancy subsequently became pregnant, a rate similar to that of women who had their IUDs electively removed to become pregnant. The study provides further data on the safety of intrauterine contraception.

---

Resumen Durante el seguimiento de 3721 usuarias del DIU Multiload, la tasa de remociones por otras razones médicas que sangrado/dolor, fué de 2.6 por 100 mujeres en tres años. La mayoría de estas remociones fueron hechas por razones que parecen no estar relacionadas con el uso del DIU. La tasa de remociones por enfermedad inflamatoria pelviana fué de 0.3 por 100 años-mujer. Las mujeres tuvieron seguimiento hasta tres años después de la remoción de sus DIU. Entre las mujeres con enfermedad inflamatoria pelviana, al menos 70% de las que desearon un embarazo lo consiguieron; una tasa similar a la de mujeres que eligieron la remoción del DIU para quedar embarazadas. El estudio proporciona más información sobre la inocuidad de la anticoncepción intrauterina.

---

Résumé Lors d'une évaluation de suivi effectuée sur 3721 utilisatrices de DIU Multiload, le taux de retrait pour des raisons médicales autres que des pertes sanguines/douleurs n'a atteint que 2,6 pour cent des femmes après trois ans. La plupart de ces retraits ont été pratiqués pour des raisons qui ne semblaient pas liées à l'utilisation du DIU. Le taux de retrait pour cause d'inflammation pelvienne s'est élevé à 0,3 pour cent femmes-an. Les femmes ont été suivies pendant des périodes allant jusqu'à trois ans après le retrait du DIU. Parmi les patientes qui avaient contracté une inflammation pelvienne, 70% au moins de celles qui souhaitaient une grossesse sont par la suite devenues enceintes; taux semblable à celui des femmes qui avaient choisi de ne plus porter leur DIU précisément pour avoir un enfant. Cette étude fournit des données supplémentaires sur la sécurité qu'apporte la contraception intrautérine.

     

Contraception for women exposedin utero to diethylstilbestrol

Although the effects ofin utero exposure to diethylstilbestrol (DES) have been extensively documented, there is an absence of information on the suitability of different contraceptives for use by DES-exposed women. This paper briefly describes some of the effects associated with DES exposure. Use of various contraceptive methods by DES-exposed women are considered in light of these effects.

---

Resumen Aunque los efectos de la exposición a dietilestilbestrol (DES) en útero ha sido documentada extensivamente, hay falta de información sobre la conveniencia de diferentes anticonceptivos para uso en mujeres expuestas a DES. Este trabajo describe brevemente algunos de los efectos asociados con la exposición a DES. Se considera el uso de distintos métodos anticonceptivos para mujeres expuestas a DES en vista a esos efectos.

---

Résumé Bien que les effets de l'exposition de l'utérus au diéthylstilboestrol (DES) fassent l'objet d'une documentation importante, on manque d'information sur les différents contraceptifs que peuvent utiliser les femmes exposées au DES. Cet article décrit brièvement certains des effets associés à l'exposition au DES et examine, en considération de ces effets, l'utilisation de diverses méthodes de contraception par les femmes qui y sont exposées.